Goldman Sachs Group Inc Xenon Pharmaceuticals Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 561,800 shares of XENE stock, worth $24.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

561,800

Previous 442,732 26.89%

Holding current value

$24.4 Million

Previous $14.9 Million 18.39%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$28.23 - $38.37 $3.36 Million - $4.57 Million	119,068 Added 26.89%	561,800 $17.6 Million
Q1 2025 May 09, 2025	BUY	$33.55 - $40.74 $1.09 Million - $1.32 Million	32,486 Added 7.92%	442,732 $14.9 Million
Q4 2024 Feb 11, 2025	SELL	$38.14 - $45.74 $1.88 Million - $2.26 Million	-49,379 Reduced 10.74%	410,246 $16.1 Million
Q3 2024 Nov 14, 2024	BUY	$36.12 - $43.96 $3.45 Million - $4.2 Million	95,452 Added 26.21%	459,625 $18.1 Million
Q2 2024 Aug 13, 2024	BUY	$36.25 - $43.75 $2.33 Million - $2.82 Million	64,399 Added 21.48%	364,173 $14.2 Million
Q1 2024 May 15, 2024	SELL	$42.66 - $50.04 $3.26 Million - $3.83 Million	-76,528 Reduced 20.34%	299,774 $12.9 Million
Q4 2023 Feb 13, 2024	BUY	$28.7 - $46.46 $3.47 Million - $5.62 Million	120,934 Added 47.36%	376,302 $17.3 Million
Q3 2023 May 14, 2024	SELL	$34.16 - $39.73 $4.13 Million - $4.8 Million	-120,934 Reduced 32.14%	255,368 $8.72 Million
Q3 2023 Nov 14, 2023	SELL	$34.16 - $39.73 $673,361 - $783,157	-19,712 Reduced 7.17%	255,368 $8.72 Million
Q2 2023 May 14, 2024	SELL	$34.84 - $43.54 $360,350 - $450,334	-10,343 Reduced 3.62%	275,080 $10.6 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $360,350 - $450,334	-10,343 Reduced 3.62%	275,080 $10.6 Million
Q1 2023 May 14, 2024	BUY	$33.46 - $40.35 $62,971 - $75,938	1,882 Added 0.66%	285,423 $10.2 Million
Q1 2023 May 11, 2023	BUY	$33.46 - $40.35 $62,971 - $75,938	1,882 Added 0.66%	285,423 $10.2 Million
Q4 2022 May 14, 2024	SELL	$33.06 - $39.43 $6.01 Million - $7.17 Million	-181,724 Reduced 39.06%	283,541 $11.2 Million
Q4 2022 Feb 13, 2023	SELL	$33.06 - $39.43 $6.01 Million - $7.17 Million	-181,724 Reduced 39.06%	283,541 $11.2 Million
Q3 2022 May 14, 2024	BUY	$30.79 - $39.82 $5.2 Million - $6.73 Million	168,951 Added 57.02%	465,265 $16.8 Million
Q3 2022 Nov 10, 2022	BUY	$30.79 - $39.82 $5.2 Million - $6.73 Million	168,951 Added 57.02%	465,265 $16.8 Million
Q2 2022 May 14, 2024	SELL	$25.44 - $35.16 $2.03 Million - $2.81 Million	-79,988 Reduced 21.26%	296,314 $9.01 Million
Q2 2022 Aug 15, 2022	SELL	$25.44 - $35.16 $10.9 Million - $15 Million	-428,023 Reduced 59.09%	296,314 $9.01 Million
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $13.9 Million - $18.3 Million	552,943 Added 322.62%	724,337 $22.1 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $1.18 Million - $2.67 Million	75,409 Added 78.56%	171,394 $5.35 Million
Q3 2021 Nov 10, 2021	BUY	$14.86 - $19.45 $1.43 Million - $1.87 Million	95,985 New	95,985 $1.47 Million

Others Institutions Holding XENE

# of Institutions

222

Shares Held

72.7M

Call Options Held

336K

Put Options Held

309K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.7B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Xenon Pharmaceuticals Inc. Transaction History